ATG Dosing for GVHD Prevention

Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Reduced Intensity Allogeneic Stem Cell Transplant

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 2
Enrollment
56 patients (estimated)
Sponsors
University of Alabama at Birmingham
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1835
NCT Identifier
NCT06265584

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.